The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.
BACKGROUND
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody against the terminal complement protein C5, potently reduces chronic intravascular hemolysis. We tested the clinical efficacy and safety of a 24-week treatment with eculizumab in 6 Korean patients with PNH.


METHODS
We enrolled 6 patients with PNH who had clinically significant hemolysis. Eculizumab was administered intravenously at 600 mg/week for the first 4 weeks followed by 900 mg at week 5 and 2nd weekly thereafter.


RESULTS
Three men and 3 women with a median age of 39.5 years (24-61 years) were enrolled. The median duration of PNH was 11 years (6-25 years). Hemolysis occurred in all patients [median lactate dehydrogenase (LDH) level, 7.95 times the upper limit of the reference range of LDH]. All patients treated with eculizumab had a rapid and sustained reduction in the degree of hemolysis. RBC transfusion requirements for 3 months were decreased from 0-12 units (median requirement, 1.5 units) to 0-6 units (median requirement, 0 units). Improvement in fatigue was noted in 4 patients. Further, 5 patients who had been receiving corticosteroids either reduced the dose or discontinued therapy. No significant adverse events related to eculizumab therapy were observed.


CONCLUSIONS
These results show that eculizumab reduces the degree of intravascular hemolysis, reduces or eliminates the requirement of RBC transfusion, and improves anemia and fatigue in patients with PNH. Eculizumab is an effective and safe option for treating Korean patients with PNH.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jin Seok
JS
Kim
Jong Wook
JW
Lee
Byoung Kook
BK
Kim
Je-Hwan
JH
Lee
Jooseop
J
Chung
Blood. 2005 Dec 1;106(12):3699-709
16051736
Lancet. 2009 Feb 28;373(9665):759-67
19144399
Br J Haematol. 1999 Feb;104(2):392-6
10050724
Blood. 2008 Feb 15;111(4):1840-7
18055865
Blood. 2009 Jun 25;113(26):6522-7
19372253
Medicine (Baltimore). 2004 May;83(3):193-207
15118546
N Engl J Med. 2006 Sep 21;355(12):1233-43
16990386
Blood. 2008 Oct 15;112(8):3099-106
18535202
N Engl J Med. 2004 Feb 5;350(6):552-9
14762182
N Engl J Med. 1995 Nov 9;333(19):1253-8
7566002